INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.
Cornelis M van TilburgRuth WittMelanie HeissKristian W PajtlerChristoph PlassIsabel PoschkeMichael PlattenInga HartingOliver SedlaczekAngelika FreitagDavid MeyrathLenka TaylorGnana Prakash BalasubramanianNatalie JägerElke PfaffBarbara C JonesTill MildeStefan M PfisterDavid T W JonesAnnette Kopp-SchneiderOlaf WittPublished in: BMC cancer (2020)
ClinicalTrials.gov, NCT03838042. Registered on 12 February 2019.